Filters

GlcNAc beta Antibody, ALEXA FLUOR 594

GlcNAc beta Antibody, ALEXA FLUOR 594 size: 100ul 332

Price 332
Size 100ul
Long name ALEXA FLUOR 594 Conjugated, GlcNAc beta Polyclonal Antibody
Also known asAnti-B4GALT7 PAb ALEXA FLUOR 594
CategoryConjugated Primary Antibodies
Conjugated with 594, ALEXA FLUOR®
Host OrganismRabbit (Oryctolagus cuniculus)
Target AntigenB4GALT7
SpecificityThis is a highly specific antibody against B4GALT7
ModificationUnmodified
Modification SiteNone
ClonalityPolyclonal
ClonePolyclonal antibody
Concentration1ug per 1ul
SourceThis antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human B4GALT7
Gene ID Number11285
Tested applicationsIF(IHC-P)
Recommended dilutionsIF(IHC-P)(1:50-200)
Crossreactivity Mouse, Rat, Human
Cross-reactive species details not every possible cross-reactivity is known, Due to limited amount of testing and knowledge
Background of the antigen Î, Î, Î, Î, The gene encoding Î, The gene encoding Î, There are seven members of the Î, There are seven members of the Î, a variant form of Ehlers-Danlos syndrome characterized by progeroid facies, a variant form of Ehlers-Danlos syndrome characterized by progeroid facies, all of which are directed to the golgi apparatus through a hydrophobic sequence at the N-terminus, all of which are directed to the golgi apparatus through a hydrophobic sequence at the N-terminus, also known as B4GALT7 or XGALT1, also known as B4GALT7 or XGALT1, is a 327 amino acid single-pass type II membrane protein that is expressed at high levels in heart, is a 327 amino acid single-pass type II membrane protein that is expressed at high levels in heart, joint hypermobility principally in digits, joint hypermobility principally in digits, mild mental retardation, mild mental retardation, moderate skin fragility, moderate skin fragility, pancreas and liver, pancreas and liver, short stature, short stature, skin hyperextensibility, skin hyperextensibility, Î, Î, &circ, &circ, «, «, ², ², ², ², ², ², ², ², ², ², ², ², ², ², -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 4 linkage to an acceptor sugar, 4 linkage to an acceptor sugar, 4 linkage to an acceptor sugar, 4-Gal-T family, 4-Gal-T family, 4-Gal-T) are type II membrane-bound glycoproteins that are substrate-specific and function to transfer galactose in a Î, 4-Gal-T) are type II membrane-bound glycoproteins that are substrate-specific and function to transfer galactose in a â, 4-Gal-T) are type II membrane-bound glycoproteins that are substrate-specific and function to transfer galactose in a â, 4-Gal-T7, 4-Gal-T7, 4-Gal-T7 is mutated in Ehlers-Danlos syndrome progeroid type (EDSP), 4-Gal-T7 is mutated in Ehlers-Danlos syndrome progeroid type (EDSP), 4-Gal-T7 uses manganese to catalyze the UDP-dependent biosynthesis of glycosphingolipids, 4-Gal-T7 uses manganese to catalyze the UDP-dependent biosynthesis of glycosphingolipids, 4-galactosyltransferases (Î, 4-galactosyltransferases (Î, 4-galactosyltransferases (Î
PurificationPurified by Protein A
Storage conditions 50% glycerol and 0, Keep refrigerated at 2 to 8 degrees Celcius for up to one year, 09% sodium azide, Store this antibody in aqueous buffered solution containing 1% BSA
Excitation emission590nm/617nm
Synonyms B4GT7_HUMAN, Beta 1, Beta 1, Beta4Gal T7, UDP Gal:beta GlcNAc beta 1, XGALT 1, XGALT1, XGPT1, Xylosylprotein beta 1, polypeptide 7, 4 GalTase 7, 4 galactosyltransferase, 4 galactosyltransferase 7, 4 galactosyltransferase 7, B4GAL T7
Properties ALEXA FLUOR they should be stored frozen at - 24°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies, C, C for long term storage and for short term at + 5°, For facs or microscopy Alexa 1 conjugate
Conjugation 594, ALEXA FLUOR®, Alexa Fluor
ConjugatedAlexa conjugate 1
Gene targetGlcNAc beta
Short nameGlcNAc beta Antibody
Technique antibodies against human proteins, antibodies for, Antibody
LabelALEXA FLUOR 594
Alternative name ALEXA FLUOR 594, GlcNAc b (Antibody to)
Alternative techniqueantibodies

Subscribe to our Newsletter